Importance of APC resistance in daily practice;Bedeutung der APC-resistenz für die praxis

Praxis

Volumn 86, Issue 5, 1997, Pages 154-161

  Lammle B ^a   Demarmels Biasiutti, F ^a   Wuillemin, W A ^a   Stucki, S ^a   Furlan, M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

APC resistance; Factor V R506Q mutation; Risk factors; Thrombophilia; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5; PROTEIN C;

ADULT; CASE REPORT; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; PHENOTYPE; POINT MUTATION; REVIEW; THROMBOCYTE DISORDER; THROMBOEMBOLISM;

ADULT; BLOOD PLATELET DISORDERS; DRUG RESISTANCE; FACTOR V; FEMALE; HUMANS; PHENOTYPE; POINT MUTATION; PROTEIN C; THROMBOEMBOLISM;

EID: 0031588537     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Dahlbäck B., Carlsson M., Svensson P. J.: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci (USA) 1993; 90: 1004-1008.
2. Bertina R. M., Koeleman B. P. C., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
3. Heijboer H., Brandjes D. P. M., Büller H. R., Sturk A., ten Cate J. W.: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516.
4. Dahlbäck B., Hildebrand B.: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to he a properly of factor V. Proc Natl Acad Sci (USA) 1994; 91: 1396-1400.
5. Koster T., Rosendaal F. R., de Ronde H., Briet E., Vandenbroucke J. P., Bertina R. M.: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506.
6. Griffin J. H., Evatt B. L., Wideman C., Fernandez J. A.: Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993.
7. Svensson P. J., Dahlbäck B.: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
8. Dahlbäck B., Hillarp A., Rosen S., Zöller B.: Resistance to activated protein C, the FV: Q506 allele, and venous thrombosis. Ann Hematol 1996; 72: 166-176.
9. Zöller B., Svensson P. J., He X., Dahlbäck B.: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
10. Roelse J. C., Koopman M. M. W., Büller H. R., ten Cute J. W., Montaruli B., van Mottrik J. A., Voorberg J.: Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Br J Haematol 1996; 92: 740-743.
11. Olivieri O., Friso S., Manzato F., Guella A., Bernardi F., Lunghi B., Girelli D., Azzini M., Brocco G., Russo C., Corrocher R.: Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-470.
12. Cumming A. M., Tait R. C, Fildes S., Yoong A., Keeney S., Hay C. R. M.: Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-727.
13. Bokarewa M. I., Bremme K., Falk G., Sten-Linder M., Egberg N., Blombäck M.: Studies on phospholipid antibodies. APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 78: 193-200.
14. Gschwandtner M. E., Lechner K., Pabinger I.: Erroneously low APC ratio in patients with lupus anticoagulant. Ann Hematol 1995; 70: 169-170.
15. Legnani C, Palareti G., Biagi R., Coccheri S., Bernardi F., Rosendaal F. R., Reitsma P. H., de Ronde H., Bertina R. M.: Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol 1996; 93: 694-699.
16. Jorquera J. I., Montoro J. M., Fernandez M. A., Aznar J. A., Aznar J.: Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
17. Trossaert M., Conard J., Horellou M. H., Samama M. M., Ireland H., Bayston T. A., Lane D. A.: Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
18. Gouault-Heilmann M., Leroy-Matheron C.: Factor V Leiden-dependent APC resistance: improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma. Thromb Res 1996; 82: 281-283.
19. Jorquera J. I., Aznar J., Fernandez M. A., Montora J. M., Curats R., Casana P.: A modification of the APC resistance test and its application to the study of patients on coumarin therapy. Thromb Res 1996; 82: 217-224.
20. Rees D. C., Cox M., Clegg J. B.: World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
21. Rosendaal F. R., Koster T., Vandenbroucke J. P., Reitsma P. H.: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508.
22. Cushman M., Bhushan F., Bovill E., Tracy R.: Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994; 72: 647.
23. Demarmels Biasiutti F., Merlo C., Furlan M., Sulzer I., Binder B. R., Lämmle B.: No association of APC resistance with myocardial infarction. Blood Coag Fibrinol 1995; 6: 456-459.
24. Emmerich J., Poirier O., Evans A., Marques-Vidal P., Arveiler D., Luc G., Aiach M., Cambien F.: Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
25. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P.: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
26. Hathmayer W. M., Haushofer A., Schön R., Fischer M.: The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 5: 51-57.
27. März W., Seydewitz H., Winkelmann B., Chen M., Nauk M., Witt I.: Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526-527.
28. Vandenbroucke J. P., Koster T., Briet E., Reitsma P. H., Bertina R. M., Rosendaal F. R.: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
29. Bokarewa M. I., Bremme K., Blombäck M.: Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-478.
30. Kierkegaard A.: Incidence of acute deep vein thrombosis in two districts. A phlebographic study. Acta Chir Scand 1980; 146: 267-269.
31. Devor M., Barren-Connor E., Renvall M., Feigal D., Kamsdell J.: Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-282.
32. Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Rosner B., Speizer F. E., Hennekens C. H.: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-762.
33. Ettinger B., Friedman G. D., Bush T., Quesenberry C. P.: Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87: 6-12.
34. Mari D., Mannucci P. M., Duca F., Bertolini S., Franceschi C.: Mutant factor V (Arg 506 Gln) in healthy centenarians. Lancet 1996: 347: 1044.
35. Mannucci P. M., Tripodi A.: Laboratory screening of inherited thrombotic syndromes. Thromb Haemostas 1987; 57: 247-251.
36. Griffin J. H., Evatt B. L., Zimmerman T. S., Kleiss A. J., Wideman C.: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
37. Miletich J. P., Sherman L., Brote G. J.: Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996.
38. Bovill E. G., Bauer K. A., Dickerman J. D., Callas P., West B.: The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73: 712-717.
39. Gandrille S., Greengard J. S., Alhenc-Gelas M., Juhan-Vague I., Abgrall J. F., Jude B., Griffin J. H., Aiach M. and the French Network on the behalf of INSERM. Incidence of activated protein C resistance caused by the Arg 506 Gln mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995; 86: 219-224.
40. Koeleman B. P. C., Reitsma P. H., Allaart C. F., Bertina R. M.: Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
41. Zöller B., Berntsdotter A., Garcia de Frutos P., Dahlbäck B.: Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
42. Radtke K. P., Lane D. A., Greengard J. S., Ehrenforth S., Griffin J. H., Scharrer I.: Combined hereditary APC resistance and AT III type II deficiency associated with venous thrombosis. Thromb Haemostas 1995; 73: 1377 (abstract).
43. Züger M., Demarmels Biasiutti F., Furlan M., Mannhalter C., Lämmle B.: Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation? Thromb Haemostas 1996; 76: 475-476.
44. Demarmels Biasiutti F., Lämmle B.: Thrombophilieabklärung: Indikation und Durchführung. Therap Umschau 1992; 49: 850-858.
45. Demarmels Biasiutti F., Lämmle B.: Prophylaxe venöser Thromboembolien - bei wem, wann und wie? Therap Umschau 1994; 51: 663-670.
46. Demarmels Biasiutti F., Stucki B., Solenthaler M., Tabler A., Furlan M., Lämmle B.: Venous thrombosis after caesarean section in a young woman with homozygous APC resistance and protein S deficiency type I. Eur J Haematol (in press 1996).
47. Dahlbäck B.: New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused bei Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemostas 1995; 74: 139-148.
48. Daly E., Vessey M. P., Hawkins M. M., Carson J. L., Gough P., Marsh S.: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
49. Jick H., Derby L. E., Wald Myers M., Vasilakis C., Newton K. M.: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983.
50. Grodstein F., Stampfer M. J., Goldhaber S. Z., Manson J. A. E., Colditz G. A., Speizer F. E., Willet W. C., Hennekens C. H.: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
51. Vandenbroucke J. P., Heimerhorst F. M.: Risk of venous thrombosis with hormone-replacement therapy. Lancet 1996; 348: 972.